CG Oncology (CG Oncology) Price-to-Tangible-Book : 4.09 (As of Jun. 08, 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Price-to-Tangible-Book?

As of today (2024-06-08), CG Oncology's share price is $34.90. CG Oncology's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $8.54. Hence, CG Oncology's Price to Tangible Book Ratio of today is 4.09.

The historical rank and industry rank for CG Oncology's Price-to-Tangible-Book or its related term are showing as below:

CGON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.09 Med: 5.14 Max: 5.14
Current: 4.09

During the past 3 years, CG Oncology's highest Price to Tangible Book Ratio was 5.14. The lowest was 4.09. And the median was 5.14.

CGON's Price-to-Tangible-Book is ranked worse than
65.79% of 1216 companies
in the Biotechnology industry
Industry Median: 2.77 vs CGON: 4.09

A closely related ratio is called PB Ratio. As of today, CG Oncology's share price is $34.90. CG Oncology's Book Value per Sharefor the quarter that ended in Mar. 2024 was $8.54. Hence, CG Oncology's P/B Ratio of today is 4.09.

CG Oncology Price-to-Tangible-Book Historical Data

The historical data trend for CG Oncology's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Price-to-Tangible-Book Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Price-to-Tangible-Book

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial			-	-	-	-	5.14

Competitive Comparison of CG Oncology's Price-to-Tangible-Book

For the Biotechnology subindustry, CG Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where CG Oncology's Price-to-Tangible-Book falls into.

CG Oncology Price-to-Tangible-Book Calculation

CG Oncology's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	34.90	/	8.538
	=	4.09

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

CG Oncology Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of CG Oncology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024